Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PLAT | P00750 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LGMN | Q99538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688602 | 1.00 | PLG (0.53) | PLGPLATLMNAMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL11075182 | 0.98 | PLG (0.52) | PLGPLATLMNAMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL1068668 | 0.98 | PLG (0.52) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL15308689 | 0.89 | PLG (0.46) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL4700703 | 0.87 | PLG (0.44) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL4700700 | 0.87 | PLG (0.44) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL2375356 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2AALDH1A1PPM1B | |
| SCHEMBL4221 | 0.85 | — | — | |
| SCHEMBL8891623 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2AALDH1A1PPM1B | |
| SCHEMBL237380 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2AALDH1A1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10245328-B2 | Gadolinium complex comprising DO3A-tranexamic acid conjugate | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-04-02 | — | — | US | claimed |
| US-20160331849-A1 | GADOLINIUM COMPLEX COMPRISING DO3A-TRANEXAMIC ACID CONJUGATE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-11-17 | — | — | US | claimed |
| EP-3093285-A1 | GADOLINIUM COMPLEX COMPRISING DO3A-TRANEXAMIC ACID CONJUGATE | Kyungpook National University Industry-Academic Cooperation Foundation (KR) | 2016-11-16 | — | — | EP | claimed |
| EP-3093285-B1 | GADOLINIUM COMPLEX COMPRISING DO3A-TRANEXAMIC ACID CONJUGATE | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2020-07-08 | — | — | EP | disclosed |
| US-10245328-B2 | Gadolinium complex comprising DO3A-tranexamic acid conjugate | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-04-02 | — | — | US | disclosed |
| US-20160331849-A1 | GADOLINIUM COMPLEX COMPRISING DO3A-TRANEXAMIC ACID CONJUGATE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-11-17 | — | — | US | disclosed |
| EP-3093285-A1 | GADOLINIUM COMPLEX COMPRISING DO3A-TRANEXAMIC ACID CONJUGATE | Kyungpook National University Industry-Academic Cooperation Foundation (KR) | 2016-11-16 | — | — | EP | disclosed |
| EP-1695977-A2 | Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines | Neurogen Corporation (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060040964-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | BAKTHAVATCHALAM RAJAGOPAL | 2006-02-23 | — | — | US | disclosed |
| US-6943199-B2 | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines | NEUROGEN CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050033048-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2005-02-10 | — | — | US | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-4578404-A | Pharmaceutical composition for treating nephritis and method for treating nephritis | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0055145-B1 | 4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-12-05 | — | — | EP | disclosed |
| EP-0041827-B1 | A N-(BENZYLIDENE) AMINOMETHYL-CYCLOHEXANE-CARBOXYLIC ACID | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-03-21 | — | — | EP | disclosed |
| US-4387102-A | 4-(N-(3',4'-Methylenedioxybenzylidene)-aminomethyl)cyclohexane-1-carboxylic acid and derivatives thereof and pharmaceutical composition thereof | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-06-07 | — | — | US | disclosed |
| US-4382955-A | ANTIINFLAMMATORY, ANTICOAGULANTS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-05-10 | — | — | US | disclosed |
| EP-0041827-A2 | A N-(benzylidene) aminomethyl-cyclohexane-carboxylic acid | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10245328-B2 | Gadolinium complex comprising DO3A-tranexamic acid conjugate | F13A1, SERPINC1, F3 | PLG 116/4885PLAT 31/4885LMNA 1923/4885 |
| US-20060040964-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, SSTR5 | PLG 1599/4885PLAT 1806/4885LMNA 2016/4885 |
| US-20160331849-A1 | GADOLINIUM COMPLEX COMPRISING DO3A-TRANEXAMIC ACID CONJUGATE | F13A1, SERPINC1, F3 | PLG 116/4885PLAT 32/4885LMNA 2113/4885 |
| US-20050033048-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, SSTR5 | PLG 1584/4885PLAT 1807/4885LMNA 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.